SCHEMBL3404672

SCHEMBL3404672

CN1CCN(C2(CNC(=O)c3ccccn3)CCN(C(=O)CC(NS(=O)(=O)c3ccc4ccccc4c3)c3ccccc3)CC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 13/20 0.44
BDKRB2 P30411 7/20 0.44
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39
RAB9A P51151 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HCN4 Q9Y3Q4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403234 0.90 BDKRB1 (0.46) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3407560 0.89 BDKRB1 (0.43) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3406741 0.88 BDKRB1 (0.47) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3406358 0.88 SMN1; SMN2 (0.43) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3407301 0.85 BDKRB1 (0.48) BDKRB1BDKRB2KMT2AMEN1
SCHEMBL4374587 0.84 BDKRB1 (0.47) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3409680 0.84 BDKRB1 (0.48) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3408526 0.82 BDKRB1 (0.49) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3405193 0.81 BDKRB1 (0.43) BDKRB1BDKRB2KMT2AMEN1ALDH1A1
SCHEMBL3410238 0.80 BDKRB1 (0.47) BDKRB1BDKRB2KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541573-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-09-24 US claimed
EP-2254867-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal Gmbh (DE) 2010-12-01 EP claimed
US-20090298812-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-12-03 US claimed
WO-2009109364-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-11 WO claimed
US-8541573-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2013-09-24 US disclosed
EP-2254867-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal Gmbh (DE) 2010-12-01 EP disclosed
US-20090298812-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-12-03 US disclosed
WO-2009109364-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298812-A1 Substituted Sulfonamide Compounds BDKRB1, BDKRB2, TRPV1 BDKRB1 1/4885BDKRB2 2/4885KMT2A 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.